TY - JOUR
T1 - Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies
AU - Kim, Sung Won
AU - Matsuo, Keitaro
AU - Fukuda, Takahiro
AU - Hara, Masamichi
AU - Matsue, Kosei
AU - Taniguchi, Shuichi
AU - Eto, Tetsuya
AU - Tanimoto, Mitsune
AU - Wake, Atsushi
AU - Hatanaka, Kazuo
AU - Nakao, Shinji
AU - Ishida, Yoji
AU - Harada, Mine
AU - Utsunomiya, Atae
AU - Imamura, Masahiro
AU - Kanda, Yoshinobu
AU - Sunami, Kazutaka
AU - Kawano, Fumio
AU - Takaue, Yoichi
AU - Teshima, Takanori
N1 - Funding Information:
Acknowledgments We would like to thank Michihiro Hidaka, Katsuji Shinagawa, Tomomi Toubai, Yuichiro Nawa, Koichiro Yuji, Akinobu Takami, Nobuharu Fujii, Yoshinobu Takemoto, and Yoshihiro Yamasaki for their aid in collecting data and responding to the queries. This work was supported by grants from the Ministry of Health, Labor and Welfare, Japan (T.T., Y.T.)
PY - 2008/10
Y1 - 2008/10
N2 - To review a current experience of unrelated bone marrow transplantation (BMT) with reduced-intensity conditioning (RIC) regimens, we conducted a nationwide survey with 77 patients (age, 25-68 years). The backbone RIC regimen was a combination of fludarabine or cladribine, busulfan or melphalan and total body irradiation at 2-4 Gy. Five patients died early, but 71 (92%) achieved initial neutrophil recovery. Thereafter, 36 patients (47%) died of therapy-related complications, 23 (30%) of whom died within day 100. Grades II-IV acute graft-versus-host disease (GVHD) occurred in 34 of the 68 evaluable patients (50%). In a multivariate analysis, a regimen containing antithymocyte globulin (ATG) was significantly associated with a decreased risk of acute GVHD (P = 0.041). Thirty-three patients are currently alive with a median follow-up of 439 days (28-2002 days), with an OS of 50% at 1 year. In conclusion, unrelated BMT with RIC regimens can be a curative treatment in a subset of patients.
AB - To review a current experience of unrelated bone marrow transplantation (BMT) with reduced-intensity conditioning (RIC) regimens, we conducted a nationwide survey with 77 patients (age, 25-68 years). The backbone RIC regimen was a combination of fludarabine or cladribine, busulfan or melphalan and total body irradiation at 2-4 Gy. Five patients died early, but 71 (92%) achieved initial neutrophil recovery. Thereafter, 36 patients (47%) died of therapy-related complications, 23 (30%) of whom died within day 100. Grades II-IV acute graft-versus-host disease (GVHD) occurred in 34 of the 68 evaluable patients (50%). In a multivariate analysis, a regimen containing antithymocyte globulin (ATG) was significantly associated with a decreased risk of acute GVHD (P = 0.041). Thirty-three patients are currently alive with a median follow-up of 439 days (28-2002 days), with an OS of 50% at 1 year. In conclusion, unrelated BMT with RIC regimens can be a curative treatment in a subset of patients.
KW - Hematologic malignancy
KW - Reduced-intensity conditioning
KW - Unrelated transplantation
UR - http://www.scopus.com/inward/record.url?scp=60049094881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60049094881&partnerID=8YFLogxK
U2 - 10.1007/s12185-008-0163-7
DO - 10.1007/s12185-008-0163-7
M3 - Article
C2 - 18797985
AN - SCOPUS:60049094881
SN - 0925-5710
VL - 88
SP - 324
EP - 330
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 3
ER -